JP2024532465A5 - - Google Patents

Info

Publication number
JP2024532465A5
JP2024532465A5 JP2024513759A JP2024513759A JP2024532465A5 JP 2024532465 A5 JP2024532465 A5 JP 2024532465A5 JP 2024513759 A JP2024513759 A JP 2024513759A JP 2024513759 A JP2024513759 A JP 2024513759A JP 2024532465 A5 JP2024532465 A5 JP 2024532465A5
Authority
JP
Japan
Application number
JP2024513759A
Other languages
Japanese (ja)
Other versions
JP2024532465A (ja
JPWO2023034818A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/075693 external-priority patent/WO2023034818A1/en
Publication of JP2024532465A publication Critical patent/JP2024532465A/ja
Publication of JP2024532465A5 publication Critical patent/JP2024532465A5/ja
Publication of JPWO2023034818A5 publication Critical patent/JPWO2023034818A5/ja
Pending legal-status Critical Current

Links

JP2024513759A 2021-09-01 2022-08-30 デュシェンヌ型筋ジストロフィーにおいてエクソン45をスキッピングするための組成物及び方法 Pending JP2024532465A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202163239671P 2021-09-01 2021-09-01
US63/239,671 2021-09-01
US202163244915P 2021-09-16 2021-09-16
US63/244,915 2021-09-16
US202163290960P 2021-12-17 2021-12-17
US63/290,960 2021-12-17
US202263298565P 2022-01-11 2022-01-11
US63/298,565 2022-01-11
US202263268577P 2022-02-25 2022-02-25
US63/268,577 2022-02-25
US202263337574P 2022-05-02 2022-05-02
US63/337,574 2022-05-02
US202263354454P 2022-06-22 2022-06-22
US63/354,454 2022-06-22
PCT/US2022/075693 WO2023034818A1 (en) 2021-09-01 2022-08-30 Compositions and methods for skipping exon 45 in duchenne muscular dystrophy

Publications (3)

Publication Number Publication Date
JP2024532465A JP2024532465A (ja) 2024-09-05
JP2024532465A5 true JP2024532465A5 (https=) 2025-09-05
JPWO2023034818A5 JPWO2023034818A5 (https=) 2025-09-05

Family

ID=83945048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513759A Pending JP2024532465A (ja) 2021-09-01 2022-08-30 デュシェンヌ型筋ジストロフィーにおいてエクソン45をスキッピングするための組成物及び方法

Country Status (9)

Country Link
US (1) US20240417429A1 (https=)
EP (1) EP4395831A1 (https=)
JP (1) JP2024532465A (https=)
KR (1) KR20240099149A (https=)
AU (1) AU2022337260A1 (https=)
CA (1) CA3230279A1 (https=)
IL (1) IL311138A (https=)
MX (1) MX2024002365A (https=)
WO (1) WO2023034818A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3829595A4 (en) 2018-08-02 2022-08-24 Dyne Therapeutics, Inc. MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
WO2025038901A1 (en) * 2023-08-17 2025-02-20 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics
WO2025072246A1 (en) * 2023-09-26 2025-04-03 Entrada Therapeutics, Inc. Compounds and methods for skipping exon 50 in duchenne muscular dystrophy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613426A1 (en) * 2014-05-21 2020-02-26 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
US20230020092A1 (en) * 2019-12-19 2023-01-19 Entrada Therapeutics, Inc. Compositions for delivery of antisense compounds
US20250243244A1 (en) * 2021-03-31 2025-07-31 Entrada Therapeutics, Inc. Cyclic cell penetrating peptides

Similar Documents

Publication Publication Date Title
JP2024519601A5 (https=)
JP2024532465A5 (https=)
JP2024524291A5 (https=)
JP2024532464A5 (https=)
BR102022025291A2 (https=)
CL2026000107A1 (es) Estimuladores de defensa de plantas
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
CN307044960S (https=)
CN307047183S (https=)
BY13175U (https=)
BY13174U (https=)
BY13170U (https=)